Immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 are promising new immunotherapy targets for the treatment of cancer and autoimmunity. Immune checkpoint reporter-based bioassays provide a simple, consistent, and reliable cell-based assay to measure Ab function throughout the drug development pipeline.
The brief chalk talk below describes the assay principals of the reporter-based bioassay that monitors the functional blockade of PD-1/PD-L1 interactions.
Latest posts by Kelly Grooms (see all)
- For the Birds: Knitting Nests for Baby Birds Might Just Help Your Health To - March 29, 2019
- Over 50 million Died in the Pandemic of 1918-A Century Later We are still Searching for a Universal Flu Vaccine - December 20, 2018
- Learning New Things About mtDNA Inheritance from a Four-Year-Old Boy and a Tenacious Team of Scientists - December 5, 2018